Corcept 10-Q: Q3 Revenue $340.5M, Net Income $126.8M, Buyback Nearly Exhausted
CORT has more than doubled off its 52-week low of $28.66.
Summary
Corcept's Q3 10-Q confirms revenue of $340.5M and net income of $126.8M with $662.3M in cash, but leaves only $5.7M on its $200M buyback authorization and discloses new insider selling plans.
Key Events · Earnings and Guidance · CORT
-
Q3 Revenue Jumps 64% to $340.5M
Product revenue rose to $340.5M from $207.6M a year earlier, with Hypercortisolism Products at $249.1M and Lifyorli contributing $91.4M in its second full quarter.
-
Net Income $126.8M, EPS $1.01
Diluted EPS was $1.01 versus $0.16 in Q3 2025; nine-month net income reached $138.0M on $761.5M of revenue.
-
Cash Builds to $662.3M
Cash, equivalents and marketable securities rose to $662.3M from $532.4M at December 31, 2025, with nine-month operating cash flow of $159.7M versus $103.5M.
-
Buyback Authorization Nearly Used Up
Only $5.7M of the $200M January 2024 repurchase program remained at September 30, 2026, after $5.7M of repurchases in the quarter at an average of $109.75 per share.
Analysis · CORT · Life Sciences
The headline numbers were already out via press release and 8-K the same day, but the 10-Q is where the balance sheet and cash flow land: $662.3M of cash and investments, up $117.7M in the quarter, and $159.7M of nine-month operating cash flow. What matters most for the stock is that only $5.7M of the $200M repurchase authorization remains — the buyback that has absorbed supply is effectively done, and the company says it does not need to raise capital. Against that, three officers and a director adopted new 10b5-1 selling plans in the quarter, and the securities class action over the relacorilant NDA was amended on August 28, 2026. The next hard date is the FDA's December 17, 2026 PDUFA target for the relacorilant Cushing's resubmission.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CORT was trading at $78.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $28.66 to $126.38. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.